GlycoMimetics, Inc. (GLYC) has 20 既知のインサイダーおよび機関投資家保有者の記録. 最大保有者は Siren, L.L.C. 8,589,064 株保有. その他の主要保有者には Invus Public Equities, L.P. および SANDELL SCOTT D.
GLYC インサイダー保有状況
最大保有者
Siren, L.L.C.
8,589,064 株
インサイダー上位保有者
| # |
氏名 |
役職 |
保有株数 |
最終申告日 |
相対規模 |
| 1 |
Siren, L.l.c. |
10 Percent Owner |
8,589,064 |
2024-07-29 |
|
| 2 |
Invus Public Equities, L.p. |
10 Percent Owner |
6,578,438 |
2024-08-09 |
|
| 3 |
Sandell Scott D |
Director |
3,588,288 |
2023-01-27 |
|
| 4 |
Semerjian Harout |
Chief Executive Officer |
695,000 |
2024-01-17 |
|
| 5 |
Bvf Partners L P/il |
10 Percent Owner |
630,453 |
2020-11-06 |
|
| 6 |
Rock Edwin |
Chief Medical Officer |
565,403 |
2024-06-24 |
|
| 7 |
Magnani John L. |
SVP of Research, CSO |
366,078 |
2022-11-14 |
|
| 8 |
Rath Chinmaya |
SVP and Chief Business Officer |
250,000 |
2024-01-17 |
|
| 9 |
Johnson Bruce S |
SVP & Chief Commercial Officer |
250,000 |
2024-01-17 |
|
| 10 |
Hahn Brian M. |
SVP Finance, CFO |
70,643 |
2024-06-20 |
|
| 11 |
Thackray Helen M. |
SVP Clinical Development, CMO |
69,000 |
2021-01-22 |
|
| 12 |
Goldberg Mark Alan |
Director |
40,000 |
2024-05-01 |
|
| 13 |
King Rachel K. |
Director |
40,000 |
2024-05-01 |
|
| 14 |
Jackson Scott Thomas |
Director |
40,000 |
2024-05-01 |
|
| 15 |
Junius Daniel M |
Director |
40,000 |
2024-05-01 |
|
| 16 |
Koenig Scott |
Director |
40,000 |
2024-05-01 |
|
| 17 |
Pearson Timothy R |
Director |
40,000 |
2024-05-01 |
|
| 18 |
Andrews Patricia S |
Director |
40,000 |
2024-05-01 |
|
| 19 |
Girard Armand |
SVP, Chief Business Officer |
29,161 |
2022-11-14 |
|
| 20 |
Gust William M. |
Director |
15,401 |
2014-01-13 |
|
GLYC の保有データがありません。
